ProductLife Group (PLG), a regulatory, scientific, compliance, and digital transformation consulting services firm for the life sciences industry, has acquired IntiQuan, a Swiss boutique specializing in pharmacometric services for the biopharmaceutical sector.
Founded in Switzerland in 2015 by Dr. Henning Schmidt, IntiQuan has rapidly established itself as a trusted provider of cutting-edge pharmacometric and statistical modelling & simulation services. The acquisition expands PLG’s portfolio of specialized solutions that support biopharmaceutical companies with drug development, adding a key set of capabilities focused on significantly reducing development risk, costs and timelines and enhancing patient safety through advanced dose-response analyses and predictive safety profiling.
With the addition of IntiQuan, PLG is now in a position to offer customers cutting-edge pharmacometrics services that include strategic consulting, pharmacokinetics/pharmacodynamics (PK/PD), population pharmacokinetics (popPK), and biosimulation services. IntiQuan is renowned for its track record of translating complex data into actionable insights across a range of therapeutic areas and modalities from pre-clinical to Phase IV. Its team of scientific experts leverages advanced mathematical modeling and simulation techniques to inform clinical study design as well as analyze and predict trial outcomes.
This acquisition represents the next step in PLG’s strategy to create a fully integrated global platform.
Xavier Duburcq, CEO of PLG, said: “We are excited to welcome the IntiQuan team to PLG. They are a very strong fit with our expertise-driven organization. Their deep and highly specialized scientific knowledge in pharmacometrics and clinical pharmacology means that we will enhance the support we provide to our clients in their drug development journey. Pharmacometrics and model-informed drug development offer regulatory grade insights that can impact key decision-making and accelerate clinical development, even eliminating the need for certain trials, in some cases.”
Dr. Henning Schmidt, Founder of IntiQuan, added: “Joining forces with PLG is a pivotal moment for IntiQuan. Our teams support IntiQuan’s clients bringing breakthrough medicines to patients and reducing both time to market and the cost of research and development through our combined solutions. We are excited to contribute our unique capabilities to PLG’s global platform and to play a key role in advancing the future of drug development.”
Dr. Stefan Wetzel, CEO of IntiQuan, said: “There is strong cultural alignment between our organizations centered on providing high-quality, innovative and customer-focused solutions. Together with our PLG colleagues, we look forward to supporting our customers with a broader set of complementary solutions, for example in regulatory services.”
